| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/12/2009 | US20090068132 Resveratrol Ferulate Compounds, Compositions Containing The Compounds, And Methods Of Using The Same |
| 03/12/2009 | US20090068129 Aminophenylbenzothiazole compounds |
| 03/12/2009 | US20090068125 Treatment for mucositis |
| 03/12/2009 | US20090068107 Enzyme regulating ether lipid signaling pathways |
| 03/12/2009 | US20090068104 Substantially Homogeneous Bio-Affecting Material Having a Pre-Determined Ratio of Bioaffecting Component to Cell Targeting Component, the Method for Making Such a Material and the Method of its use |
| 03/12/2009 | US20090068103 Aptamers labeled with 68ga |
| 03/12/2009 | US20090068101 A1 Adenosine Receptor Antagonists |
| 03/12/2009 | US20090068098 Antibodies and related molecules that bind to 58p1d12 proteins |
| 03/12/2009 | US20090068094 Inhibitors of endo-exonuclease activity for treating cancer |
| 03/12/2009 | DE102007043177A1 Use of a composition containing an ingredient e.g. hydrated silicic acid, sorbitol, glycerin, polyethylene glycol, sodium lauryl sulfate, sodium fluoride, titanium dioxide, xanthan and carrageen for the treatment of hematoma |
| 03/12/2009 | DE102007042754A1 Substituierte 6-Phenylnikotinsäuren und ihre Verwendung Substituted 6-Phenylnikotinsäuren and their use |
| 03/12/2009 | DE102007042154A1 Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel Arylsulfonylaminomethyphosphonsäure derivatives, their preparation and their use as medicaments |
| 03/12/2009 | CA2727971A1 Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| 03/12/2009 | CA2714921A1 Pharmaceutical compositions |
| 03/12/2009 | CA2704284A1 Co-crystals and pharmaceutical compositions comprising the same |
| 03/12/2009 | CA2703831A1 Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| 03/12/2009 | CA2699172A1 Compositions and methods for delivery of poorly soluble drugs |
| 03/12/2009 | CA2698847A1 Bis-aromatic compounds useful in the treatment of inflammation |
| 03/12/2009 | CA2698838A1 Novel phenylurea derivatives, inhibitors of the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 03/12/2009 | CA2698771A1 Microrna signatures in human ovarian cancer |
| 03/12/2009 | CA2698755A1 Mitochondrial compositions and uses thereof |
| 03/12/2009 | CA2698753A1 Pyrazolo-pyridines as tyrosine kinase inhibitors |
| 03/12/2009 | CA2698742A1 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| 03/12/2009 | CA2698721A1 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| 03/12/2009 | CA2698713A1 Compositions and methods for treating immunological and inflammatory diseases and disorders |
| 03/12/2009 | CA2698707A1 Release of antibiotic from injectable, biodegradable polyurethane scaffolds for enhanced bone fracture healing |
| 03/12/2009 | CA2698695A1 Method of treating glaucoma using rasagiline |
| 03/12/2009 | CA2698683A1 Dheas inhalation compositions |
| 03/12/2009 | CA2698680A1 Improved brimonidine compositions for treating erythema |
| 03/12/2009 | CA2698671A1 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer |
| 03/12/2009 | CA2698670A1 A novel controlled release-niacin formulation |
| 03/12/2009 | CA2698665A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 03/12/2009 | CA2698661A1 Method to ameliorate oxidative stress and improve working memory via pterostilbene administration |
| 03/12/2009 | CA2698651A1 Eye drop containing dibenz [b,e] oxepin derivative |
| 03/12/2009 | CA2698528A1 Animal parasite-control method using insect growth regulators |
| 03/12/2009 | CA2698514A1 Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol |
| 03/12/2009 | CA2698511A1 Substituted pyrimidinyl-amines as protein kinase inhibitors |
| 03/12/2009 | CA2698498A1 Antiviral topical formulations in the form of a bio-adhesive gel |
| 03/12/2009 | CA2698486A1 Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 03/12/2009 | CA2698377A1 Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis |
| 03/12/2009 | CA2698306A1 Derivatives of n-phenylacetamide as inhibitors of the enzyme soat1 for pharmaceutical and cosmetic use |
| 03/12/2009 | CA2698304A1 Novel derivatives of phenylureas, inhibitors of the soat-1 enzyme, pharmaceutical and cosmetic compositions containing them |
| 03/12/2009 | CA2698299A1 Derivatives of n-phenylacetamide, inhibitors of the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 03/12/2009 | CA2698287A1 Antibodies and related molecules that bind to 24p4c12 proteins |
| 03/12/2009 | CA2698062A1 Thiadiazinone derivatives |
| 03/12/2009 | CA2697941A1 Piperazine derivative having affinity for the histamine h3 receptor |
| 03/12/2009 | CA2697934A1 1,3-dihydroisoindole derivatives |
| 03/12/2009 | CA2697744A1 A method for treating diabetes |
| 03/12/2009 | CA2697737A1 Method for promoting expression of p53, and p53 expression promoter for use in the method |
| 03/12/2009 | CA2697546A1 Phosphadiazine hcv polymerase inhibitors iv |
| 03/12/2009 | CA2697537A1 Azithromycin for treatment of skin disorders |
| 03/12/2009 | CA2697500A1 2,3-substituted azaindole derivatives for treating viral infections |
| 03/12/2009 | CA2697454A1 2-carboxy substituted indole derivatives and methods of use thereof |
| 03/12/2009 | CA2697451A1 Tetracyclic indole derivatives and methods of use thereof |
| 03/12/2009 | CA2697375A1 2, 3-substituted indole derivatives for treating viral infections |
| 03/12/2009 | CA2696943A1 Acetamide stereoisomer |
| 03/12/2009 | CA2696824A1 Compounds and compositions as kinase inhibitors |
| 03/12/2009 | CA2696752A1 Complexes of rna and cationic peptides for stimulation of the innate immune system |
| 03/12/2009 | CA2696129A1 Use of travoprost for treating hair loss |
| 03/12/2009 | CA2695556A1 Use of carolaction or derivatives thereof to prevent or treat bacterial biofilms |
| 03/12/2009 | CA2690011A1 Dentifrice compositions for treating xerostomia |
| 03/12/2009 | CA2684037A1 Compounds with anti-cancer activity |
| 03/11/2009 | EP2034017A1 Gene involved in immortalization of human cancer cell and use thereof |
| 03/11/2009 | EP2034015A1 Immunostimulatory oligonucleotide and pharmaceutical application thereof |
| 03/11/2009 | EP2033999A1 Ozonized surfactant |
| 03/11/2009 | EP2033972A1 Screening method for candidate drugs |
| 03/11/2009 | EP2033968A1 Target of rapamycin modulators of and use thereof |
| 03/11/2009 | EP2033965A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 03/11/2009 | EP2033963A1 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| 03/11/2009 | EP2033962A1 Tetracyclic indolopyridines as EG5 inhibitors |
| 03/11/2009 | EP2033959A1 Tetrahydropyranoquinoline derivatives |
| 03/11/2009 | EP2033956A1 A new class of histone deacetylase inhibitors |
| 03/11/2009 | EP2033955A1 Urea derivatives of 1H-pyrazol-4-carboxylic acid with neutrophil chemotaxis inhibiting activity |
| 03/11/2009 | EP2033954A1 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor |
| 03/11/2009 | EP2033953A1 Vanilloid receptor modulators |
| 03/11/2009 | EP2033952A1 Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity |
| 03/11/2009 | EP2033951A2 2-Piperazine-pyridines useful for treating pain |
| 03/11/2009 | EP2033950A1 Substituted tetracycline compounds |
| 03/11/2009 | EP2033652A1 Treatment of inflammatory bowel disease |
| 03/11/2009 | EP2033650A1 Inhibitor of expression of nuclear transcription factor ap-1, and pharmaceutical product and product using the inhibitor |
| 03/11/2009 | EP2033649A1 Pharmaceutical composition for treatment of ocular hypertension |
| 03/11/2009 | EP2033648A2 Sustained release drug delivery system containing codrugs |
| 03/11/2009 | EP2033647A1 Agent against psychosocial stresses |
| 03/11/2009 | EP2033646A1 Prophylactic and/or therapeutic agent for rheumatoid arthritis |
| 03/11/2009 | EP2033645A1 Isoquinoline derivatives and methods of use thereof |
| 03/11/2009 | EP2033644A1 Spiroindene and spiroindane compounds |
| 03/11/2009 | EP2033643A1 Compressed preparation |
| 03/11/2009 | EP2033642A1 Pharmaceutical composition effective against biofilms |
| 03/11/2009 | EP2033641A1 Process of preparation of extracts rich in proanthocyanidins |
| 03/11/2009 | EP2033640A2 Beta-lapachone for the treatment of lung cancer |
| 03/11/2009 | EP2033639A2 Beta-lapachone for the treatment of colon cancer |
| 03/11/2009 | EP2033638A2 Beta-lapachone for the treatment of pancreatic cancer |
| 03/11/2009 | EP2033637A1 Therapeutic or prophylactic agent for leukemia |
| 03/11/2009 | EP2033636A1 Method of purifying pravastatin |
| 03/11/2009 | EP2033635A1 Short-chain fatty acid derivatives for treating pruritus |
| 03/11/2009 | EP2033634A1 Agent for increasing testosterone level |
| 03/11/2009 | EP2033633A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 03/11/2009 | EP2033632A1 5-HT3 receptor antagonists for the teatment of myocardial infarction, stroke, thrombosis and atherosclerosis |
| 03/11/2009 | EP2033631A2 Pravastatin pharmaceutical formulations and methods of their use |
| 03/11/2009 | EP2033630A1 A novel controlled release-niacin formulation |